跳至主要内容
临床试验/NCT05550571
NCT05550571进行中(未招募)不适用

Treatment of Ruptured Wide-Neck Aneurysms With Nautilus Device Assisted Occlusion

EndoStream Medical10 个研究点 分布在 2 个国家目标入组 45 人开始时间: 2022年12月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
45
试验地点
10
主要终点
The proportion of subjects experiencing death or stroke

研究概览

简要总结

The study aims to evaluate the safety and probable benefit of a medical device to treat wide-neck ruptured brain aneurysms.

详细描述

Patients with ruptured brain aneurysms will be treated with the Nautilus, then will be followed up for one year.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is ≥18 years old
  • Subject who presents with an angiographically confirmed, wide neck intracranial saccular, acutely ruptured aneurysm. Wide neck is defined as 4-7mm.
  • Aneurysm dome ≥5 mm.
  • Subject is neurologically stable with a Hunt & Hess score of I, II, or III.
  • In the opinion of the treating physician, placement of the Nautilus is technically feasible and clinically reasonable.
  • The subject or authorized representative is able to provide informed consent and has signed the IRB-approved informed consent form.
  • Subject must be able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.

排除标准

  • Subject with any neurological deficit occurred within the last 180 days; defined as previous non-aneurysmal subarachnoid hemorrhage or any other non-aneurysmal intracranial hemorrhage, stroke, transient ischemic attacks (TIA), concussion, head trauma, cranial surgery, radiation therapy to the head.
  • Premorbid mRS score ≥
  • Subject has another aneurysm which, in the Investigator's opinion, will require treatment within the follow-up period (1 year).
  • Women of child-bearing potential age (18-55) who cannot provide a negative pregnancy test.
  • Subject with other serious comorbidities that carry a high risk of neurologic events such as:
  • Significant acute or chronic cardiovascular disease such as myocardial infarction within the past 180 days
  • Uncorrectable coagulation abnormality
  • Uncontrolled diabetes mellitus with target organ injury
  • Organ failure of kidney, liver, heart or lungs
  • Arteriovenous malformation or arteriovenous fistula, Moyamoya disease, or any other vasoconstriction
  • Premorbid intracranial tumor or hematoma
  • Severe or unstable conditions or diseases (e.g., non-significant neurological deficit, cancer, hematologic or coronary disease) or chronic conditions that in the opinion of the investigator may increase the risk associated with study participation for study device administration or may interfere with the interpretation of study results.
  • Extreme vessel stenosis or tortuosity or other vascular anomalies that would prevent delivery of the device to the target.
  • Comorbidities that may preclude obtaining follow-up DSA.
  • Known allergy to Nickel and/or Heparin that cannot be medically treated.
  • Subject is currently participating in another interventional clinical study.
  • Subject with a relative contraindication to angiography (i.e., allergy to contrast media, coagulopathy, etc.)

结局指标

主要结局

The proportion of subjects experiencing death or stroke

时间窗: 12 months

The proportion of subjects experiencing death or stroke in treated vascular territory measured using the NIH stroke scale

次要结局

  • device-related Serious Adverse Event(12 months)
  • Technical Success(During procedure)
  • Distribution of parent vessel compromise(12 months)
  • The proportion of subjects with complete aneurysm occlusion(12 months)
  • aneurysm occlusion at the conclusion of the treatment procedure(During procedure)
  • Coil/Device entanglement(During procedure)

研究者

发起方
EndoStream Medical
申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验